Burning Rock Biotech vs CareDx
BNR and CDNA side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BNR and CDNA compare
CareDx grew revenue faster over the last twelve months (38.9% versus 4.6% for Burning Rock Biotech).
CareDx keeps more of each dollar of sales as profit, with a net margin of 25.9% compared with −10.3% at Burning Rock Biotech.
CareDx scores higher on the StockData Score (12 against 4 for Burning Rock Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BNR | CDNA |
|---|---|---|
| Size and price | ||
| Market cap | – | $4.3B |
| Share price | $13.24 | $81.17 |
| Change, 1 year | 8.6% | 386% |
| Change, 5 years | −92.3% | 88.7% |
| Beta (5Y) | 1.74 | 1.52 |
| Employees | 667 | 765 |
| StockData Score | ||
| Total score | 4 | 12 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 4 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 34.0× |
| P/S | – | 8.6× |
| P/B | – | 9.1× |
| EV/EBITDA | – | 29.9× |
| Fair value | – | $66.02 |
| Margin of safety | – | −22.9% |
| Growth | ||
| Revenue growth (TTM) | 4.6% | 38.9% (better) |
| Revenue growth, 5Y average | 4.6% | 14.6% (better) |
| Net income growth (TTM) | – | 82.6% |
| Profitability | ||
| Gross margin | 74.7% | – |
| Operating margin | −10.2% | 23.4% (better) |
| Net margin | −10.3% | 25.9% (better) |
| FCF margin | −6.2% | – |
| Return on equity | −9.9% | 33.0% (better) |
| Return on invested capital | −72.5% | 69.8% (better) |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.00 |
| Current ratio | 2.99 (better) | 2.31 |
| Altman Z-score | – | 15.36 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 1.8% | 102% |
| Held by insiders | 19.0% | 4.8% |
| Insider net buying, 12 months | $11.6M (better) | −$18.1M |
| Short interest, % of float | – | 14.4% |
Go deeper
- BNR stock overview
- BNR income statement
- BNR valuation and score
- CDNA stock overview
- CDNA income statement
- CDNA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.